Publications by Medical Specialty - Oncology
These publications were authored or co-authored by Quest Diagnostics staff.
- Adult Medicine
- Clinical and Lab healthcare professionals
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Family medicine practitioners
- General Health and Wellness
- Geriatrics/Age Management
- Health Information Technology
- Infectious Disease
- Internal Medicine
- Nurse practitioners
- Pathology, Anatomic
- Pathology, Laboratory Medicine
- Physician assistants
- Prescription Drug Monitoring
- Primary Care
- Sports Medicine
- Toxicology/Pain Management
- Women's Health/OB/GYN
Authors: Padda MS, Si WM.
J Med Case Rep. 2019 Mar;13(1):89. doi: 10.1186/s13256-018-1967-6.
Disclaimer: One or more of the authors of this publication were employed at the time by AmeriPath, a subsidiary of Quest Diagnostics.
Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010-2017.
Authors: Amatuni GS, Currier RJ, Church JA, Bishop T, Grimbacher E, Nguyen AA, Agarwal-Hashmi R, Aznar CP, Butte MJ, Cowan MJ, Dorsey MJ, Dvorak CC, Kapoor N, Kohn DB, Markert ML, Moore TB, Naides SJ, Sciortino S, Feuchtbaum L, Koupaei RA, Puck JM.
Pediatrics. 2019 Jan 25: doi: 10.1542/peds.2018-2300. [Epub ahead of print]
Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ("5 + 1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia.
Authors: Saini NY, Cerny J, Furtado VF, Desmond A, Zhou Z, Raffel G, Puthawala I, Bednarik J, Shanahan L, Miron PM, Woda B, Ramanathan M, Nath R.
Am J Hematol. 2019 Feb;94:209-215.
Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia.
Authors: Chun K, Wenger GD, Chaubey A, Dash DP, Kanagal-Shamanna R, Kantarci S, Kolhe R, Van Dyke DL, Wang L, Wolff DJ, Miron PM.
Cancer Genet. 2018 Dec;228-229:236-250.
PAX5, NOTCH3, CBFB, and ACD drive an activated RAS pathway and monosomy 7 to B-ALL and AML in donor cell leukemia.
Authors: Assi R, Mahfouz R, Owen R, Gunthorpe M, Chehab FF, Bazarbachi A.
Bone Marrow Transplant. 2018 Dec 10. doi: 10.1038/s41409-018-0419-7. [Epub ahead of print]
A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.
Authors: Li Y, Devlin JJ.
Value Health. 2018 Jul;21(7):893-894. Epub 2018 Apr 5.
Authors: Ihrler S, Guntinas-Lichius O, Haas C, Mollenhauer M.
Pathologe. 2018;39(1):11-17. doi: 10.1007/s00292-017-0407-5. [Epub ahead of print]
Disclaimer: One or more of the authors of this publication were employed at the time by DermPath, a subsidiary of Quest Diagnostics.
Revised prevalence estimate of possible Hereditary Xerocytosis as derived from a large U.S. Laboratory database.
Authors: Kaufman HW, Niles JK, Gallagher DR, Rivera A, Alper SL, Brugnara C, Snyder LM.
Am J Hematol. 2018;93(1):E9-E12
Authors: Liu J, Zheng S, Li JH, Guo Y, Zhang LT, Gao XH, Chen HD
Am J Dermatopathol. 2018 Jan 16. doi: 10.1097/DAD.0000000000001073. [Epub ahead of print]
Managing Variant Interpretation Discrepancies in Hereditary Cancer: Clinical Practice, Concerns, and Desired Resources.
Authors: Zirkelbach E, Hashmi S, Ramdaney A, Dunnington L, Ashfaq M, Nugent EK, Wilson K.
J Genet Couns. 2017 Dec 20. doi: 10.1007/s10897-017-0184-6. [Epub ahead of print]